Careers  |  Sign In  |  Register  |   Twitter

FDA Votes to Conduct Further Study on Cardiovascular Risk of Testosterone Drugs

After 2.3 million men in the U.S. used testosterone therapies last year, a FDA advisory panel voted 20-1 that drug developers should conduct additional studies on the cardiovascular risk that these drugs pose, an article published by Bloomberg News says. A study published last year revealed that testosterone supplements increase the risk of heart attack, stroke, or death by 29 percent, though these results were disputed by other studies. Nevertheless, two major producers of testosterone products, AbbVie Inc. and Eli Lilly & Co., have agreed to comply with the FDA in order to determine the potential cardiovascular risk associated with these drugs.

Read the article published by Bloomberg News.